Myeloproliferative Neoplasms (MPN) Latest Advances

Clinical and genetic features of Ph-negative myeloproliferative neoplasms with dual-driver gene positivity.

Journal: Hematology (Amsterdam, Netherlands)

Published: September 01, 2026

Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 30, 2026

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017;130(26):2848-2859.

Journal: Blood

Published: August 27, 2026

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Journal: Leukemia & lymphoma

Published: August 20, 2026

Myeloproliferative Neoplasms.

Journal: The New England journal of medicine

Published: August 19, 2026

Role of JAK2 V617F in Myeloproliferative Neoplasms: From Mutation to Manifestation: A Review.

Journal: Nigerian medical journal : journal of the Nigeria Medical Association

Published: August 17, 2026

First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations.

Journal: BMJ case reports

Published: August 10, 2026

Genomic abnormalities in myeloproliferative neoplasms

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Profile of Philadelphia Chromosome Negative (Ph-) Myeloproliferative Neoplasm with Special Emphasis on Vascular Thrombotic Events and the Response to Cytoreductive Therapy in Polycythemia Vera and Essential Thrombocythemia Patients: A Single Center Study from Kerala.

Journal: The Journal of the Association of Physicians of India

Published: August 03, 2026

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

Journal: Seminars in hematology

Published: July 26, 2026

The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting.

Journal: Seminars in hematology

Published: July 12, 2026

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms.

Journal: Cancers

Published: July 10, 2026

Myeloproliferative Neoplasms (MPN) Latest Advances

Find the Latest Research About Myeloproliferative Neoplasms (MPN)

Clinical and genetic features of Ph-negative myeloproliferative neoplasms with dual-driver gene positivity.

Clinical and genetic features of Ph-negative myeloproliferative neoplasms with dual-driver gene positivity.

Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm

Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017;130(26):2848-2859.

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017;130(26):2848-2859.

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Myeloproliferative Neoplasms.

Myeloproliferative Neoplasms.

Role of JAK2 V617F in Myeloproliferative Neoplasms: From Mutation to Manifestation: A Review.

Role of JAK2 V617F in Myeloproliferative Neoplasms: From Mutation to Manifestation: A Review.

First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations.

First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations.

Genomic abnormalities in myeloproliferative neoplasms

Genomic abnormalities in myeloproliferative neoplasms

Profile of Philadelphia Chromosome Negative (Ph-) Myeloproliferative Neoplasm with Special Emphasis on Vascular Thrombotic Events and the Response to Cytoreductive Therapy in Polycythemia Vera and Essential Thrombocythemia Patients: A Single Center Study from Kerala.

Profile of Philadelphia Chromosome Negative (Ph-) Myeloproliferative Neoplasm with Special Emphasis on Vascular Thrombotic Events and the Response to Cytoreductive Therapy in Polycythemia Vera and Essential Thrombocythemia Patients: A Single Center Study from Kerala.

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting.

The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting.

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms.

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms.